Algernon Pharmaceuticals Inc. (CSE: AGN)
Canada
· Delayed Price · Currency is CAD 0.0850
-0.0050 (-5.56%)
Sep 20, 2024, 4:00 PM EDT
Algernon Pharmaceuticals Revenue
Revenue
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
n/a
Market Cap
2.45M
Revenue Chart
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Green Thumb Industries Inc. | 1.52B |
| Trulieve Cannabis Corp. | 1.59B |
| Cresco Labs Inc. | 1.01B |
| Ayr Wellness Inc. | 635.84M |
| Planet 13 Holdings Inc. | 139.22M |
| Jushi Holdings Inc. | 360.23M |
| Grown Rogue International Inc. | 28.83M |
| iAnthus Capital Holdings, Inc. | 229.29M |
Algernon Pharmaceuticals News
- 5 weeks ago - Algernon Pharmaceuticals Announces Closing of Private Placement - GlobeNewsWire
- 6 weeks ago - Algernon Pharmaceuticals Announces Increase to Private Placement - GlobeNewsWire
- 7 weeks ago - Algernon Pharmaceuticals Announces Private Placement - GlobeNewsWire
- 4 months ago - Algernon Pharmaceuticals Engages ICP Securities Inc. for Automated Market Making Services - GlobeNewsWire
- 5 months ago - Algernon NeuroScience and the Centre for Human Drug Research to Present DMT Phase 1 Stroke Clinical Data at the Interdisciplinary Conference on Psychedelic Research June 6 – 8th, 2024 - GlobeNewsWire
- 6 months ago - Algernon Pharmaceuticals CEO Christopher J. Moreau to Be Featured on Radius Research's Pitch, Deep Dive and Q&A Webinar on April 16th, 2024 - GlobeNewsWire
- 6 months ago - Algernon Pharmaceuticals to Move Forward with Psychedelic Drug DMT Stroke Research Program as its Lead Asset - GlobeNewsWire
- 6 months ago - Algernon Pharmaceuticals Announces Closing of the Acquisition of its Chronic Cough Research Program by U.S. Based Seyltx for USD $2M and a 20% Equity Position - GlobeNewsWire